21 December 2021 in Russian Clinical Laboratory Diagnostics
It has been established that the non-neuronal cholinergic system is related to the oncogenesis which increases the attractiveness of its components as the promising markers of oncologic diseases. The purpose of this work is to evaluate the clinical significance of the analysis of the activity of acetyl cholinesterase as a new marker of gliomas. The activity of acetyl cholinesterase was assessed by photo colorimetric analysis according to the Hestrin method recalculating the activity of the enzyme in the tumor tissue per 1 g of protein, and in the blood - by 0.1 g of hemoglobin. The data obtained in the primary tumors of the brain (28) in the tissue of the brain of persons who died as a result of injury (6) and in whole blood of patients with gliomas (28) and practically healthy people (10) were compared with the use of a number of statistical programs. A significant decrease in the activity of acetyl cholinesterase in tumor tissue and in whole blood is revealed as the degree of anaplasia of tumors increases, starting with Grade II. It is for the first time that a significant direct correlation was noted showing the consistency between the decrease in the activity of acetyl cholinesterase in the tumor tissue of the brain and blood. Bioinformatic analysis showed the connection of the enzyme of acetyl cholinesterase with proteins of the PI3K-AKT and Notch signaling pathways providing antiapoptotic and proliferative effects. The found dependences provide new insights into understanding of the mechanisms of gliomas genesis and can be used for selection of new diagnostic markers of brain tumors.
2 October 2025 in Allergology and Immunology in Paediatrics
Relevance. Down syndrome is one of the most common genetic diseases worldwide. People with this syndrome are at risk for developing immunodeficiency conditions. The article discusses the results of a study of TREC and KREC concentrations in children with Down syndrome. The aim of the study was to determine the concentration of TREC and KREC in children with Down syndrome compared with healthy children. Materials and methods. A prospective study was conducted to determine the content of TREC and KREC in the bloo d of children and adolescents with Down syndrome. Results. It was found that the co ncentration of TREС in children with Down syn drome is significantly lower than in healthy children of the appropriate age, which indicates a violation in the development of the T-cell link of immunity. A similar pattern is observed for KREС levels, which indicates a violation of the maturation of B-lymphocytes responsible for the synthesis of antibodies. Conclusion. This study highlights the importance of early diagnosis and monitoring of the immune status in children with Down syndrome by determining the conc entration of TREС and KREС, which will allow timely corrective measures and prevent the development of complications.
31 July 2026 in Allergology and Immunology in Paediatrics
Relevance. An urgent task of modern medicine is to assess the effectiveness of the immune response to hepatitis B vaccination in children with Down syndrome. Studies show that most children with Down syndrome do not develop sufficient levels of protective antibodies after standard hepatitis B vaccination. Assessing the effectiveness of the immune response will allow for the development of personalized vaccination programs for children with Down syndrome. Objective: to assess the effectiveness of the immune response to hepatitis B vaccination in children with Down syndrome by studying the concentration of specific antibodies in their blood serum and comparing the results with their vaccination status. Materials and methods. A cross-sectional cohort study was performed with the participation of 102 children with Down syndrome aged from 1 to 17 years. The concentration of IgG antibody titers to hepatitis B was analyzed, based on age and vaccination status (full, partial vaccination, no vaccination). Results. 73 (71,6 %) children had completed hepatitis B vaccination among all the subjects. The concentration of hepatitis B antibodies in children with Down syndrome decreases significantly with age, reaching a titer below 10 mIU/ml in most adolescents over 12 years of age. In children with complete vaccination in the 1–5 years group, the geometric mean of antibody titers was 24.5 mIU/ml, in the 6–11 years group, it was 26.7 mIU/ml, while in children aged 12–17 years, the antibody titers were below the protective threshold, with a geometric mean of 2.13 mIU/ml, indicating the need for further revaccination under certain conditions. Correlation analysis revealed a negative relationship between age and antibody levels (r = −0.3205, p = 0.0057). Children with Down syndrome do not have an epidemiological advantage for hepatitis B in “indicator” groups Conclusion. Among children with Down syndrome aged 12 years and older who have received a full course of hepatitis B vaccination, there is a very high percentage of those who do not have a p rotective antibody titer. It is recommended to develop a personalized approach to revaccination and monitor post-vaccination antibodies to maintain an adequate level of protection.